Podcasts about miami cancer institute

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

So You've Been Diagnosed With Cancer: Now What? That “now what” is the big question everyone faces when they hear those dreaded worlds: You have cancer. Tune into this episode to hear some helpful advice from Heather's “chief of staff” (aka one of the best friends) Amy Dieterich, and Dr. Starr Mautner, a Board-certified surgeon with clinical expertise in breast surgical oncology of the Breast Center at Miami Cancer Institute, a part of Baptist Health South Florida. Bio: Starr Mautner, M.D., F.A.C.S. Dr. Mautner is a board-certified breast surgical oncologist at the Miami Cancer Institute (MCI) in Miami, Florida. She specializes in performing breast surgical procedures for women with breast cancer, high risk lesions, or women with a genetic predisposition to breast cancer. She grew up in South Florida and earned her undergraduate and medical school degrees as part of the University of Miami's 7-year Medical Scholars Program. She then completed her general surgery residency at Weill Cornell's New York Presbyterian Hospital and clinical fellowship in breast surgical oncology at Memorial Sloan Kettering Cancer Center before moving back to Miami to join the Miami Cancer Institute in 2015. She is the co-chair of the Memorial Sloan Kettering Alliance Education Committee and is very involved in community engagement and educational programs in South Florida. She is also the lead physician for breast surgical oncology clinical trials at MCI and a member of the Breast Cancer Alliance Medical Advisory Board. In her free time, she enjoys spending time with her husband and children exploring Miami or traveling on adventures around the world together. Bio: A dedicated philanthropist with a deep passion for supporting families and children, Amy Dieterich is committed to making a meaningful impact in healthcare and advocacy. As a member of the Chairman's Circle at NYU Hospital and the Children's Advisory Council of New York-Presbyterian Komansky Center for Children's Health, she plays a vital role in shaping initiatives that enhance pediatric care. Her leadership extends to Breakthrough T1D, where she has spearheaded giving campaigns and initiatives to advance research and support for those affected by Type 1 Diabetes. Beyond her philanthropic efforts, she is a strong advocate for women, fostering connections and uplifting women in business. A devoted mom of four boys, she embraces adventure and cherishes traveling with her family, always seeking new experiences and meaningful ways to give back. Find Yonni & Heather here https://www.herhealthcompass.com/

Robot-assisted technology has revolutionized surgical fields such as general surgery and urology—could interventional radiology be the next frontier? In this episode of the BackTable podcast, host Dr. Jacob Fleming explores the transformative potential of robotic-assisted percutaneous biopsies and ablations with experts Dr. Govindarajan “Raj” Narayanan from the Miami Cancer Institute and Dr. Sean Tutton from UC San Diego. --- This podcast is supported by: Quantum Surgical https://www.quantumsurgical.com/ --- SYNPOSIS Dr. Narayanan begins by sharing his initial interest in robotic applications for tumor ablations, aiming to maximize efficiency in his practice. Dr. Tutton then highlights the advantages of robotics for probe placement, especially in challenging cases. The two doctors discuss the logistics of the robotic system, including setup, imaging, and access choices. They also reflect on the learning curve associated with robotics and how it gradually enhances procedural efficiency while reducing mental fatigue. This improvement allows them to take on more complex cases with confidence. Overall, both experts agree that robotics has the potential to democratize minimally invasive procedures, offering new opportunities for skill development and advancement within the field of interventional radiology. --- TIMESTAMPS 00:00 - Introduction to the Podcast 03:30 - Developing an Interest in Robotics 10:44 - Integration of Robotics in the Procedural Suite 13:27 - Logistics of Robot System 18:38 - Planning for Percutaneous Access 22:39 - Future Implications of Robotics on Training Programs 35:51 - Efficiency and Volume Management with Robotics 40:39 - Learning Curves for Robotic Procedures 48:09 - Conclusion and Final Thoughts --- RESOURCES Quantum Surgical Epione Robot: https://www.quantumsurgical.com/epione/ ACCLAIM Trial: https://www.sio-central.org/ACCLAIM-Trial

Robot-assisted technology has revolutionized surgical fields such as general surgery and urology—could interventional radiology be the next frontier? In this episode of the BackTable podcast, host Dr. Jacob Fleming explores the transformative potential of robotic-assisted percutaneous biopsies and ablations with experts Dr. Govindarajan “Raj” Narayanan from the Miami Cancer Institute and Dr. Sean Tutton from UC San Diego. --- This podcast is supported by: Quantum Surgical https://www.quantumsurgical.com/ --- SYNPOSIS Dr. Narayanan begins by sharing his initial interest in robotic applications for tumor ablations, aiming to maximize efficiency in his practice. Dr. Tutton then highlights the advantages of robotics for probe placement, especially in challenging cases. The two doctors discuss the logistics of the robotic system, including setup, imaging, and access choices. They also reflect on the learning curve associated with robotics and how it gradually enhances procedural efficiency while reducing mental fatigue. This improvement allows them to take on more complex cases with confidence. Overall, both experts agree that robotics has the potential to democratize minimally invasive procedures, offering new opportunities for skill development and advancement within the field of interventional radiology. --- TIMESTAMPS 00:00 - Introduction to the Podcast 03:30 - Developing an Interest in Robotics 10:44 - Integration of Robotics in the Procedural Suite 13:27 - Logistics of Robot System 18:38 - Planning for Percutaneous Access 22:39 - Future Implications of Robotics on Training Programs 35:51 - Efficiency and Volume Management with Robotics 40:39 - Learning Curves for Robotic Procedures 48:09 - Conclusion and Final Thoughts --- RESOURCES Quantum Surgical Epione Robot: https://www.quantumsurgical.com/epione/ ACCLAIM Trial: https://www.sio-central.org/ACCLAIM-Trial

In this episode, Mark Davis, Adjunct Professor at the Forsyth Institute and former COO of the Miami Cancer Institute, shares his journey in operational turnarounds, driving patient satisfaction, and fostering a culture of excellence. Join this engaging discussion on the evolving challenges in healthcare and how strategic discipline and cultural alignment can lead to transformative success.

In this episode, Mark Davis, Adjunct Professor at the Forsyth Institute and former COO of the Miami Cancer Institute, shares his journey in operational turnarounds, driving patient satisfaction, and fostering a culture of excellence. Join this engaging discussion on the evolving challenges in healthcare and how strategic discipline and cultural alignment can lead to transformative success.

In this episode, Mark Davis, Adjunct Professor at the Forsyth Institute and former COO of the Miami Cancer Institute, shares his journey in operational turnarounds, driving patient satisfaction, and fostering a culture of excellence. Join this engaging discussion on the evolving challenges in healthcare and how strategic discipline and cultural alignment can lead to transformative success.

CancerNetwork® spoke with John Paul Diaz, MD, about uterine transposition, a surgical technique aiming to preserve fertility in women undergoing radiotherapy for pelvic tumors. Diaz is the chief of gynecologic oncology, director of robotic surgery, director of the Center of Excellence in Minimally Invasive Gynecologic Surgery at Baptist Health, and lead physician for Clinical Trials in Gynecologic Oncology at Miami Cancer Institute.  Of note, Diaz discussed the outcomes associated with 2 procedures conducted at his practice, as well as challenges associated with the development and implementation of the procedure. Additionally, he spoke about the next steps in developing and raising awareness of the procedure. Diaz foregrounded the discussion by highlighting the simplicity of the procedure, which he stated was similar to a hysterectomy. Unlike a hysterectomy, uterine transposition entails a temporary relocation of the uterus to the anterior abdominal wall, which preserves it for fertility while removing it from the radiation field. Furthermore, Diaz described the collaboration between Baptist Health and Memorial Sloan Kettering Cancer Center, including a partnership with Mario M. Leitao, Jr., MD, FACOG, FACS, who holds the largest series in the United States in performing uterine transpositions. He explained that the collaboration was conducive for expanding patient populations that may benefit from this surgery. Diaz then underlined outcomes related to 2 uterine transposition procedures he conducted at Baptist Health. He described a favorable outcome with one patient who had completed the procedure 3 months prior who may be able to become pregnant in the future. The second patient was undergoing radiotherapy, with plans to undergo the second stage of the surgery in following months. Diaz then highlighted a distinction between uterine transposition and other fertility preservation measures in that it preserves the entire uterus so patients can still carry a child, whereas other radiation therapy techniques do not. He then highlighted patients who are eligible for this procedure, particularly among women who want to preserve their fertility with pelvic tumors requiring radiation that might otherwise sterilize the uterus. Challenges related to the development and implementation of the procedure were discussed, with particular emphasis placed upon quality of life following treatment. Additionally, he emphasized the idea of patient-driven improvements in treatment outcomes, which he hoped could be applied to help more women preserve their fertility. Diaz continued by emphasizing the novelty of the procedure, explaining that experiences with it are growing while surgery success rates increase with global collaboration and technique sharing. He followed by underscoring the primary goal of cancer eradication, stressing that treatment for progressing disease takes precedence over fertility, and in those situations, fertility may be compromised. He further outlined key short-term outcomes in patients undergoing uterine transposition, particularly as they related to maintaining uterine perfusion and mitigating post-operative complications. For long-term outcomes, he highlighted the goal for patients to be disease-free and capable of carrying a live birth. Additionally, Diaz underscored a challenge related to raising awareness for this procedure, highlighting efforts he has undertaken to inform surgeons in the colorectal cancer field about the availability of this procedure as an option for this patient population. He suggested that colleague identification of eligible patients, effective referral, and increased proliferation of procedure knowledge may be effective in overcoming this challenge. Diaz concluded by highlighting next steps for the procedure as they relate to expanding access for patients, increasing knowledge of the procedure among physicians, and developing novel techniques for uterine preservation during radiotherapy. He highlighted the “exciting” development of this procedure, which he suggested might have been inconceivable a few years ago, in achieving better outcomes for young women diagnosed with pelvic tumors.

In this powerful episode, Pastor Bill White sits down with Michael Zinner, renowned CEO of the Miami Cancer Institute, to explore the intersection of faith, healing, and leadership in the fight against cancer. Together, they discuss the challenges and breakthroughs in cancer care, and how strong leadership can inspire hope in the face of adversity. With personal stories and professional insights, this conversation highlights the importance of leadership in transforming lives and the power of community in battling life's greatest challenges.

Yuliya Linhares, MD is a medical oncologist specializing in the comprehensive treatment of lymphoma and serves as chief of Lymphoma Services at Miami Cancer Institute. In this video, Dr. Linhares provides an overview of cutaneous T-cell lymphoma (CTCL) and discusses some strategies for shortening the diagnostic journey of this rare cancer.The diagnosis of CTCL is often challenging; as a result, delays in diagnosis (and subsequent work-up and treatment) can be significant. Part of the reason is the variability in how individual patients present with CTCL and its subtypes. Because mycosis fungoides progresses slowly, some patients may not experience progression beyond their initial symptoms, even beyond 10 years. Patients with mycosis fungoides or Sézary syndrome also have overlap in manifestations; in fact, Sézary syndrome was once classified as a malignant, leukemic variant of mycosis fungoides but is now recognized as a distinct CTCL subtype.Patients with mycosis fungoides may progress through three phases of skin symptoms. The first may feature little more than transient red, scaly areas of skin on the buttocks and torso. The plaques may be hyper- or hypopigmented. As such, these symptoms can be easily misidentified as common skin conditions such as eczema or psoriasis. The variability of signs and symptoms also adds to the challenge of making a timely, clear-cut diagnosis.In the second phase, patients with progressing disease may develop palpable, scaly, reddish-brown plaques that appear on any portion of the body. Over time, the affected areas of skin may grow, merging with other affected regions. Patients' skin presentation during this stage can vary considerably: Some patients may experience severe pruritus or pain in these scaly bumps, which can result in sleep disturbances and other challenges to quality of life. Other patients may remain asymptomatic other than the skin's appearance.Disease presentation is a bit more consistent in patients who have progressed to the third phase of skin symptoms. Some patients may develop mushroom-shaped skin tumors that can cause skin ulceration and infection. Even for patients with mycosis fungoides reaching this phase of skin progression, malignant spread is uncommon (only 10% will experience metastases to major organs).While patients with Stage III mycosis fungoides experience widespread erythema (over 80% of body surface area), erythroderma is a consistent feature of Sézary syndrome. This rash will often be associated with severe pruritus and peeling.In addition to erythroderma and B2 blood involvement, patients with Sézary syndrome will typically have several other characteristic signs: generalized lymphadenopathy, opportunistic infections, and alopecia. The liver and possibly the spleen will be enlarged, and patients often have very thick, coarse skin on the soles of the feet and palms of the hands (i.e., palmoplantar keratoderma).Diagnosis is usually made with a patient history, complete physical exam, blood tests, biopsy of skin lesions, computed tomography imaging, and sometimes lymph node biopsy and/or bone marrow biopsy. These methods can also be useful in determining the stage of disease, especially whether the lymph nodes have been involved and whether the cancerous cells have spread to blood and other organs. In addition to eczema and psoriasis, the differential diagnosis may include nonspecific dermatitis, lichen, lupus, pseudolymphoma, parapsoriasis, and toxidermia.To learn more about CTCL, visit our Cutaneous T-Cell Lymphoma (CTCL) Learning Center page. https://checkrare.com/cutaneous-t-cell-lymphoma-2/

Chadi and guest Dr. Manmeet Ahluwalia, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, delve into the latest breakthroughs in primary brain cancers. As a distinguished expert in brain metastases and primary brain tumors, Dr. Ahluwalia provides invaluable insights into clinical trial design, enrollment challenges, and the complexities of brain tumor development. Together, they explore the landscape of surgical and therapeutic interventions, uncovering advances in survival rates, quality-of-life enhancements, and promising therapeutic agents targeting specific mutations, as well as mechanisms of treatment resistance and the ongoing pursuit of effective solutions. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

While advancements in oral medicine are improving the treatment landscape for head and neck cancer, routine dental care and preventative oral cancer screenings can help identify head and neck cancers early. In this episode, Alessandro Villa, DDS, PhD, MPH, chief of Oral Medicine, Oral Oncology, and Dentistry at Baptist Health South Florida's Miami Cancer Institute, emphasizes the proactive role dentists can play in early identification of cancer—as well as the need for equitable access to dental care—and explores how a cross-disciplinary cancer care team and patient education work in tandem to better manage complications from head and neck treatment.   “It is widely known that any patient with a diagnosis of head and neck cancer who is scheduled to receive treatment with chemo and radiation therapy should see a dentist prior to starting cancer therapy. We should make sure that access is available for this patient.” —Alessandro Villa, DDS, PhD, MPH    Alessandro Villa, DDS, PhD, MPH Chief of Oral Medicine, Oral Oncology, and Dentistry Miami Cancer Institute, Baptist Health South Florida Miami, FL   This episode was made in connection with the ACCC education program Multidisciplinary Approaches to Head & Neck Cancer Care in partnership with Head and Neck Cancer Alliance and the American Society of Radiation Oncology (ASTRO) and with support provided by EMD Serono.      Resources:    Multidisciplinary Approaches to Head & Neck Cancer Care    Head and Neck Patient and Caregiver Resources    Making the Case for Head & Neck Cancer Patient Care Navigators   

The saying "saving your skin" takes on extra meaning when you are outdoors. Living a "sun and fun" lifestyle can come with a price -- the sun's damaging UV rays and the risk of skin cancer. Hopefully, you practice safety by using sunscreens, hats and clothing to mitigate those harmful rays. Some people forget that sun damage and skin cancer can be synonymous. As spring and summer approach, how do we avoid skin cancer? And if it leaves a concerning spot on the skin, what do we do next? Host: Jonathan Fialkow, M.D., Chief Medical Officer at Baptist Health who oversees Population Health, Primary Care, Cardiology, Endocrinology and other Medical Specialties Guest: Michael Raish, M.D., Mohs Micrographic Surgeon and Dermatologist, Baptist Health Miami Cancer Institute 

CancerNetwork® spoke with Govindarajan Narayanan, MD about his practice becoming the first in the United States to successfully surgically treat a patient with a liver tumor using the Epione robot, as well as the process of transitioning from CT-based image guidance to the robotic workstation in his care.1  Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, both of Baptist Health South Florida, described how the use of Epione may save significant amounts of time while performing microwave ablation, cryoablation, and irreversible electroporation (IRE). Developers designed the robotic device to simplify several probe procedures, helping make large tumors more predictable to manage.2  According to Narayanan, Epione is suitable for use in any patient for whom his practice typically performs image-guided ablations. Additionally, the device may “level the playing field” by allowing those with less experience to give highly accurate surgery, thereby increasing the availability of physicians who can offer these treatments across multiple practices. Narayanan also described some of the potential challenges associated with adopting the Epione robot in clinic, such as adapting to the physical space that it occupies in the operating room. The device may also pose a steep learning curve with respect to procedures involving multiple needles such as cryoablation and IRE, as it is necessary to set a path that won't cause any deflections of the needle.  Looking ahead, Narayanan said that future technological developments may allow users to operate the robot remotely, allowing patients to receive surgery at a treatment center even if a practicing physician is not physically present. “It's very exciting to be at the forefront of bringing such a cutting-edge technology to mainstream clinical practice,” Narayanan said. “Everything is done with one click, so it saves a significant amount of time. And because you're not doing multiple check scans when you place the needles, you're saving on radiation time.” References 1.     First patient treated in the United States with Quantum Surgical's Epione® robot. News release. Quantum Surgical. May 24, 2023. Accessed November 6, 2023. https://shorturl.at/lzH01 2.     Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6

Lung cancer is the No. 1 cancer killer in the United States every year. And while smoking rates across the country are on a downward trend, the effects from smoking can linger for years. The American Cancer Society suggests there are over 5 million smokers or previous smokers who should undergo annual screenings for lung cancer – with early detection being the best shot at beating the deadly disease. Guests: Jonathan Fialkow, M.D., Chief of Cardiology at Baptist Hospital and Chief Population Health Officer at Baptist Health.  Mark Dylewski, M.D., Thoracic and Robotic Surgeon, Miami Cancer Institute

Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.

Chadwick Boseman, Oscar-award winning actor died at 43 of colon cancer.  44-year old superstar Ryan Reynolds gets a colonoscopy after losing a bet, revealing several polyps that were discovered and removed successfully.  As if there aren't enough headlines about the dangers of colorectal cancer lately, listen up! Colorectal cancers are getting diagnosed more frequently at a younger age and prevention is key. If you turn to face it head on early enough you can beat it before it beats you. Host: Jonathan Fialkow, M.D., Chief of Cardiology at Baptist Hospital and Chief Population Health Officer at Baptist Health.  Guest: Sarah Joseph, M.D., Medical Oncologist at Miami Cancer Institute who specializes in gastrointestinal cancers.

An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation." Dr. Garje reviews the new evidence and the latest recommendation update for the use of 177Lu-PSMA-617, a radioligand therapy in patients with PSMA-positive mCRPC, along with it's implications for clinicians and patients. For more information, visit www.asco.org/genitourinary-cancer-guidelines.   TRANSCRIPT Brittany Harvey: Hello, and welcome to the ASCO Guidelines Podcast series, brought to you by the ASCO Podcast Network; a collection of nine programs, covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows, including this one at: asco.org/podcast. My name is Brittany Harvey, and today I'm interviewing Dr. Rohan Garje from Miami Cancer Institute in Miami, Florida, lead author on, ‘Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation'. Thank you for being here, Dr. Garje. Dr. Rohan Garje: Absolutely. Thank you so much for having me, Brittany. Brittany Harvey: Great. And first, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The full Conflict of Interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. Garje, do you have any relevant disclosures that are directly related to this guideline topic? Dr. Rohan Garje: Yes. I have received institutional research funding from Pfizer, Amgen, Endocyte, and AAA, who have drugs for the treatment of prostate cancer. Brittany Harvey: Excellent. Thank you for those disclosures. Then getting into the content of this guideline update, what prompted this rapid update to the ‘ASCO Guideline on Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer', which was previously published in 2014? Dr. Rohan Garje: Since 2014, there have been several new drugs that have been approved for prostate cancer management. And most recently in March 2022, FDA has approved 177Lutetium-PSMA-617 for patients with PSMA scan-positive metastatic castration-resistant prostate cancer. This led to the team from ASCO to develop this new rapid recommendation update. Now, this approval actually has been based on the efficacy data published in Vision clinical trials. To give you a little background about Lutetium, it is a novel β-energy-emitting radioligand therapy. In this particular study, this agent was combined with best standard of care, and compared to best standard care alone, in men with metastatic castration-resistant prostate cancer, who had a positive PSMA scan. Briefly, the study was both clinically and statistically positive, and has shown improvement in both overall survival and radiographic progression-free survival. The median overall survival was about 15.3 months with the combination therapy, compared to 11.3 months with the standard care arm. Brittany Harvey: Great. And then based off this new evidence and the new approval from the FDA for 177 Lutetium-PSMA-617, what are the updated recommendations from the guideline panel? Dr. Rohan Garje: The panel recommends the use of 177 Lutetium-PSMA-617 as a treatment option in patients with PSMA PET/CT positive metastatic castration-resistant prostate cancer, who have been previously treated with at least one line of androgen receptor pathway inhibitor, and at least one line of prior axon-based chemotherapy. Brittany Harvey: Great. And then, what should clinicians know as they implement the use of this drug and this new recommendation by the guideline panel? Dr. Rohan Garje: A very good question. It is important to select patients based on a positive PSMA scan. That is, all the metastatic lesions should be positive on the PSMA scan, and there should not be any large lymph nodes or visceral organ metastatic disease that are PSMA negative. Additionally, physicians can use Gallium 68 PSMA-11, or F-18 Piflufolastat as radio tracers for PSMA scan to determine eligibility. Additionally, there are several other factors that need to be considered, such as: the patient should have baseline good blood counts, as well as renal function to be eligible for this therapy, as this treatment has a potential to cause mild suppression and impairment of renal function. The most common side effects associated with this drug are fatigue, dry mouth, dry eyes, and nausea. The treatment in general is for four to six cycles. Each cycle is for every six weeks. The fifth and sixth cycles should be considered only if patients are responding well to the therapy and have no significant toxicities. It is also important for the physicians to note that there are several additional treatment options for patients with metastatic castration-resistant prostate cancer, who had prior anti-androgen docetaxel therapy. They include; Cabazitaxel, PARP inhibitors for patients who have mutations in DNA repair, gene mutations such as BRCA1 and BRCA2, and immunotherapy with Pembrolizumab for patients with MSI-high status, or tumor mutation burden greater than 10. Brittany Harvey: Thank you for describing that nuance behind the recommendations. So then, in addition, how does this update impact patients with metastatic castration-resistant prostate cancer? Dr. Rohan Garje: 177 Lutetium-PSMA-617 is the first radioligand therapy approved for the treatment of prostate cancer. Previously, we had Radium-223 as a radiopharmaceutical, but this particular agent is unique in the sense, it is a radioligand therapy where it is chelated to PSMA. So, it is very targeted therapy which works for both bone and visceral organ metastasis. So, this is an exciting treatment option for patients, as it has been shown to have improvement in overall survival. This adds to the current treatment choices of anti-androgens, chemotherapy, as well as targeted therapies for prostate cancer patients. Brittany Harvey: Great. It's exciting to have a new treatment option for patients. So then finally, what are the outstanding questions regarding systemic therapy for metastatic castration-resistant prostate cancer? Dr. Rohan Garje: We are at an exciting stage in the management of prostate cancer. In the last decade, we have seen several new drugs; some are specific targeted agents, some are specific immunotherapy agents. Now, we are entering into this realm of radioligand therapy, which is very exciting. There are several other novel radioligand therapies such as; Actinium, Thorium, Lead, which are being evaluated in the treatment of prostate cancer. So, in the next several years, we will see several new drugs that have been developed. In addition, there are other agents called T-cell-engaging therapies, which are being evaluated to improve the outcomes. So, the last decade definitely has seen a lot of new improvements, but we are so excited that several new treatment choices are now available for patients, and several are in clinical evaluation. So, the future is bright for the patients with prostate cancer, where we have several new treatment choices to improve their outcomes. Brittany Harvey: It sounds like an exciting time for developments in prostate cancer. So, I want to thank you so much for your time today, Dr. Garje, and thank you for all of the work you did to update this guideline. Dr. Rohan Garje: Thank you so much. I really thank ASCO leadership and the team for giving me this opportunity, and thank you, Brittany, for hosting me on this podcast. Brittany Harvey: And thank you to all of our listeners for tuning into ASCO Guidelines Podcast series. To read the full guideline, go to: www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, available in iTunes or the Google Play store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe, so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.    

It's common for cancer programs and practices to struggle with timely treatment education, consent gathering, and adherence tracking, especially when an oral oncolytic is prescribed. These challenges are due in part to older solutions that are no longer benefiting all patients equally. To better address these concerns, Baptist Health South Florida, Miami Cancer Institute in Florida turned to technology solutions that were already being used by the health system and that were well understood by their healthcare teams and patients. By using these technologies and implementing existing staffing resources, Miami Cancer Institute staff are providing high-quality cancer care without having to dip deeper into its operating budget. Guest: Morgan Nestingen, MSN, APRN, AGCNS-BC, NEA-BC, OCN, ONN-CG Director of Nursing Services, Patient Intake and Navigation Baptist Health South Florida, Miami Cancer Institute Resources: Improving Oral Oncolytic Compliance with Technology 2022 ACCC Innovator Award Details ACCC 39th National Oncology Conference Care Coordination: The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics Leveraging Pharmacy Informatics to Standardize Pharmacists' Review of Oral Oncolytics for Hospitalized Patients Defining the Role of Oncology Advanced Practitioners Improve Oral Oncolytic Workflow and Reduce Treatment Delays with a Pharmacist Collaborative Practice Agreement This podcast is part of a special series on the 2022 ACCC Innovator Award winners. For a deeper dive into this content, visit ACCC's Innovator Award website.

Dr. Guenther Koehne is the Deputy Director and Chief of Blood and Marrow Transplant and Hematologic Oncology at the Baptist Health South Florida Miami Cancer Institute. They are part of a clinical trial for an approach that protects healthy cells from the toxic side-effects of targeted blood cancer treatments with a focus on acute myeloid leukemia (AML). Guenther explains," And then, we have the opportunity to administer medications or CAR-T cells, for example, post transplantation, that are specifically targeting CD33, which then presumably allows us to specifically target residual leukemia cells." "So, my institution, Miami Cancer Institute, and before that, I was at Memorial Sloan Kettering Cancer Center, where I implemented the purification of stem cells from the stem cell product, from the donor stem cell product, allowing to deplete the T cells and other cells that were not necessarily needed for a successful transplant while we have a purified stem cell population. And on this clinical trial, we can now use the purified stem cells and send them to a specified laboratory to silence or down regulate the expression of CD33, using CRISPR technology so that the end product after this step will include a donor-derived stem cell population that is CD33 negative." #MiamiCancerInstitute #VorBio #CellTherapy #BloodCancers #AML #AcuteMyeloidLeukemia #AML #Leukemia #ClinicalTrial #Miami miamicancerinstitute.com Download the transcript here

Dr. Guenther Koehne is the Deputy Director and Chief of Blood and Marrow Transplant and Hematologic Oncology at the Baptist Health South Florida Miami Cancer Institute. They are part of a clinical trial for an approach that protects healthy cells from the toxic side-effects of targeted blood cancer treatments with a focus on acute myeloid leukemia (AML). Guenther explains," And then, we have the opportunity to administer medications or CAR-T cells, for example, post transplantation, that are specifically targeting CD33, which then presumably allows us to specifically target residual leukemia cells." "So, my institution, Miami Cancer Institute, and before that, I was at Memorial Sloan Kettering Cancer Center, where I implemented the purification of stem cells from the stem cell product, from the donor stem cell product, allowing to deplete the T cells and other cells that were not necessarily needed for a successful transplant while we have a purified stem cell population. And on this clinical trial, we can now use the purified stem cells and send them to a specified laboratory to silence or down regulate the expression of CD33, using CRISPR technology so that the end product after this step will include a donor-derived stem cell population that is CD33 negative." #MiamiCancerInstitute #VorBio #CellTherapy #BloodCancers #AML #AcuteMyeloidLeukemia #AML #Leukemia #ClinicalTrial #Miami miamicancerinstitute.com Listen to the podcast here

It's natural to reach for advanced analytics, machine learning, and other potentially transformational technologies in healthcare. That's especially true in oncology where speed to diagnosis and speed to care are critical. However, there are fundamental data needs that must be mastered if we are going to be successful. Today we talk with C.K. Wang, Chief Medical Officer at COTA about these fundamentals: A surprising number of physicians and health delivery organizations still do not fully grasp the importance of data nor how to use it to enhance care delivery Many provider organizations cling to a disabling view of HIPAA and other privacy laws that make them slow to share critical data when it's needed most Data completeness and data fidelity issues continue to fly under the radar due to issues 1 and 2 Bottom line: You cannot hope to succeed in risk-based models until you stop putting all your patients into the same bucket. And you can't do that until you've mastered these data fundamentals. Learn how COTA helps its customers overcome these issues and puts them on a path to succeed in value-based care. Plus, we take a look at how COTA is helping the Miami Cancer Institute explore racial and ethnic disparities in the diagnosis and treatment of cancer.   For full show notes and links, visit: https://thehcbiz.com/195-the-data-fundamentals-that-enable-value-based-care-c-k-wang/

Abby is resolving a medical issue which has both she and Jim making regular trips to the Miami Cancer Institute. A pre-Covid regularvacationer, Mike from Canada, returns to his home away from home after almost 3 years. Jim has a dream and his take on his behavior is self condemnation. Finally , teens try to shock the adult world through the pretense of outrageous behavior and or speech. It is Jim's belief that most of the talk is just.talk.

Abby is resolving a medical issue which has both she and Jim making regular trips to the Miami Cancer Institute. A pre-Covid regularvacationer, Mike from Canada, returns to his home away from home after almost 3 years. Jim has a dream and his take on his behavior is self condemnation. Finally , teens try to shock the adult world through the pretense of outrageous behavior and or speech. It is Jim's belief that most of the talk is just.talk.

Have you been screened for a genetic predisposition towards breast cancer? I have. My results returned a "Variant of Unknown Significance", or VUS.What is a Variant of Unknown Significance? It's a common question and I am pleased to have Dr. Mártir-Negrón, a medical geneticist at Miami Cancer Institute, part of Baptist Health South Florida, and trained in internal medicine, genetic diagnosis and the treatment of patients with hereditary disorders to help answer this question! Laura: Dr. Mártir-Negrón, I understand when we get our genetic testing back and read through the results, sometimes we get what is called a variant of unknown significance, also referred to as VUS. Can you explain what this means and how it impacts breast cancer treatment decisions?Dr. Mártir-Negrón: What a variant of unknown significance means is that there was a change that was found in you. But guess what, we all have changes in our genes; that's what  makes us unique and who we are. The only ones that we know will cause problems are the ones that we call pathogenic. Based on data, we know that 90% of these inconclusive changes are benign. At the lab we'll continue to review, and when there is more data, they will reach out to whoever ordered the test to inform them of any new findings. The person who ordered the test is the one that is going to receive the reclassification. Again, 90% of the cases are benign, so we call it negative until proven otherwise. In terms of treatment, we don't do anything with that information and no action is taken. But, if we give recommendations, it's not because of the inconclusive work, it's what we're seeing in terms of one's family history. With the inconclusive result, you're always going to have that change, you were born with that change. What it changes is our interpretation. When we see that somebody has a variant of unknown significance or is inconclusive, we look at ClinVar. ClinVar is a part of the National Institute of Health and aggregates information about genomic variation and its relationship to human health. Obviously, no names or personal data are disclosed. What we do is when we see any inconclusives, we will look at ClinVar to see what all the labs are saying.Laura Carfang: That's such a great point. ClinVar is a freely available public archive of human genetic variations and interpretations of the relationships to disease and other conditions. Abigail Johnston:  Just another reason why talking to the right doctor about the right topic is so important. Dr. Mártir-Negrón is a geneticist, you don't mind saying you don't know, whereas other doctors in other specialties often avoid saying "I don't know something" and it's very important to remember that. 

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC). In the video series, Bazhenova and Albrecht discussed the following: ·      Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC ·      EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data ·      Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies ·      EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions ·      Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC ·      Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC ·      Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC To watch more videos in CancerNetwork®'s Between the Lines™ series, visit cancernetwork.com/between-the-lines. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Today on Breast Cancer Conversations, we continue the conversation of  germline breast cancer mutations and the weighted complexities of passing on genes that may lead to developing breast cancer, or other types of cancer. We are joined by:Dr. Mártir-Negrón:  a medical geneticist at Miami Cancer Institute, a world class cancer center part of Baptist Health South Florida. Dr. Mártir-Negrón, is trained in internal medicine, genetic diagnosis and the treatment of patients with hereditary disorders. Dr. Mártir-Negrón,  is board certified in medical genetics and internal medicine. Her clinical interests include genetic cancer risk assessment, breast cancer, colon cancer and ovarian cancer. We are also joined today with a panel of women, moms, and daughters, who have all been affected by either breast cancer or a germline genetic mutation, which increases one's risk for developing cancer. Abigail Johnston: who is living with metastatic stage iv breast cancer and carries the ATM gene Abigail's mother, Beverly Schroeder who was diagnosed with early stage breast cancer only to discover later on that she too carries the ATM gene.  Trish Chambers Balas three-time breast cancer survivor joins us with her daughter Maddie Balas. We also have Stephanie McLeod Estevez.  After losing her mom to metastatic breast cancer, Stephanie decided not to rush into getting genetic testing. She focused on grieving the loss of her mother and starting her own family. It wasn't till after she became a mom and was diagnosed with breast cancer herself, that she discovered that she carries the BRCA2 genetic mutation.We don't have any control of our genes. Let me just start it with that. Our genes are the things that are in our DNA, it is something that we have no control over.  This is not about blame. This is not about looking at somebody and saying it's your fault. It's about how do you deal with a genetic mutation that runs in a family. Welcome to the conversation.Episodes you may also like:Understanding the Complexities of Genetic Testinghttps://www.survivingbreastcancer.org/podcast/episode/c045cfab/49-understanding-the-complexities-of-genetic-testing-an-interview-with-genetics-counselor-fatima-amir-ms-lgcLymphedema, the ATM Gene & Humor:https://www.survivingbreastcancer.org/podcast/episode/c09b7b3c/18-the-boob-ambassador-lymphedema-the-atm-gene-and-humorJoin our Survivingbreastcancer.org community:https://www.survivingbreastcancer.org/Become a member:https://www.survivingbreastcancer.org/communityAttend an event:https://www.survivingbreastcancer.org/eventsRead our blog:https://www.survivingbreastcancer.org/breast-cancer-blogFollow us on social media:Instagram: https://www.instagram.com/survivingbreastcancerorg/Twitter: https://twitter.com/SBC_orgFacebook:https://www.facebook.com/Survivingbreastcancerorg

Today on Breast Cancer Conversations, we discuss germline breast cancer mutations and the weighted complexities of passing on genes that may lead to developing breast cancer, or other types of cancer. We are joined by:Dr. Mártir-Negrón:  a medical geneticist at Miami Cancer Institute, a world class cancer center part of Baptist Health South Florida. Dr. Mártir-Negrón, is trained in internal medicine, genetic diagnosis and the treatment of patients with hereditary disorders. Dr. Mártir-Negrón,  is board certified in medical genetics and internal medicine. Her clinical interests include genetic cancer risk assessment, breast cancer, colon cancer and ovarian cancer. We are also joined today with a panel of women, moms, and daughters, who have all been affected by either breast cancer or a germline genetic mutation, which increases one's risk for developing cancer. Abigail Johnston: who is living with metastatic stage iv breast cancer and carries the ATM gene Abigail's mother, Beverly Schroeder who was diagnosed with early stage breast cancer only to discover later on that she too carries the ATM gene.  Trish Chambers Balas three-time breast cancer survivor joins us with her daughter Maddie Balas. We also have Stephanie McLeod Estevez.  After losing her mom to metastatic breast cancer, Stephanie decided not to rush into getting genetic testing. She focused on grieving the loss of her mother and starting her own family. It wasn't till after she became a mom and was diagnosed with breast cancer herself, that she discovered that she carries the BRCA2 genetic mutation.We don't have any control of our genes. Let me just start it with that. Our genes are the things that are in our DNA, it is something that we have no control over.  This is not about blame. This is not about looking at somebody and saying it's your fault. It's about how do you deal with a genetic mutation that runs in a family. Welcome to the conversation.Episodes you may also like:Understanding the Complexities of Genetic Testinghttps://www.survivingbreastcancer.org/podcast/episode/c045cfab/49-understanding-the-complexities-of-genetic-testing-an-interview-with-genetics-counselor-fatima-amir-ms-lgcLymphedema, the ATM Gene & Humor:https://www.survivingbreastcancer.org/podcast/episode/c09b7b3c/18-the-boob-ambassador-lymphedema-the-atm-gene-and-humorJoin our Survivingbreastcancer.org community:https://www.survivingbreastcancer.org/Become a member:https://www.survivingbreastcancer.org/communityAttend an event:https://www.survivingbreastcancer.org/eventsRead our blog:https://www.survivingbreastcancer.org/breast-cancer-blogFollow us on social media:Instagram: https://www.instagram.com/survivingbreastcancerorg/Twitter: https://twitter.com/SBC_orgFacebook:https://www.facebook.com/Survivingbreastcancerorg

Tamara is an entrepreneur, health and wellness ambassador, speaker, and author. As an entrepreneur with more than 20 years of experience in accounting and finance, Tamara has worked in the public and private sectors and her clients range in various industries from technology to media. She is an author of two children's books — Hair to the Queen! And Teo the Great — which open the door for families to discuss difficult subjects, Tamara also shares her experiences and knowledge in her monthly blog, A Cup of T , offering quick tips for self-care and self-fulfillment, especially for on-the-go women. Serving as a board member on several local organizations, strengthening South Florida's Haitian community, helping breast cancer research, and creating diverse and inclusive initiatives in schools. Tamara is also a founding member of A Day with Santa, a not-for-profit organization that raises funds and distributes toys to over 5,000 underprivileged Haitian children annually. Moreover, Tamara is an impact speaker and continues to work closely with Baptist Health of South Florida and Miami Cancer Institute as an ambassador raising awareness, and bridging the gap, when it comes to cultural disparities and the misinformation surrounding cancer care.

hello, Hello, HELLO friends!  Were back with another episode to close out American Pharmacist Month.  This month were bringing pharmacists all month long and we are excited to welcome Dr. Miami, we mean Dr. Aisha Shokoya, PharmD, BCPS!  She giving us all the insight on being a Clinical Oncology Pharmacist. Listen in and learn! Also, it's still American Pharmacist Month and we are passionate about you knowing your pharmacist.  Go to www.knowyourpharmacist.org to for a free download of 10 Questions to Ask Your Pharmacist!   Here's what you'll learn in this episode: All about the COVID 19 vaccine for children under 12 years old. The role of a Clinical Oncology Pharmacist How to help manage the side effects of cancer treatment. Why self-care for Doctors is so important.   Links COVID-19 Vaccines for Children and Teens | CDC - Ms Rx Geek About our Guests: Dr. Aisha Shokoya Aisha Shokoya, PharmD, BCPS is a clinical oncology pharmacist at the Miami Cancer Institute. She graduated with a PharmD degree from Palm Beach Atlantic University and afterwards completed her post graduate residency training at the Cleveland Clinic. Outside of helping cancer patients on a daily basis, Aisha enjoys blogging and teaching the next generation of pharmacists. She is also Founder and creator of her brand MsRxGeek where she helps inspire, motivate and teach those who are passionate about the field pharmacy.   Connect with Dr. Aisha on Instagram: instagram.com/ms.rxgeek   Enjoying the show, leave us a review on your favorite podcast platform and connect with 3 friends TALK: 3friendsTALK.com instagram.com/3friendsTALK facebook.com/3friendsTALK

Annual screening mammograms can detect breast cancer at an early stage when it is most treatable, but often mammograms show other irregularities in the breasts that are not cancerous, such as cysts, calcifications, and dense breast tissue. What exactly do these findings mean? And where can women turn for guidance concerning these benign breast conditions? Host, Jonathan Fialkow, M.D. welcomes Deepa Sharma, D.O.,  a primary care doctor and the lead physician at the benign breast clinic at Miami Cancer Institute. 

Jonathan Fialkow, M.D. hosts a panel of breast cancer experts to answer the most common questions women have after receiving a cancer diagnosis. Listen in to their wide-ranging discussion about treatments, genetic testing, fertility issues, support services and the importance of finding an experienced multidisciplinary care team.Guests:Louise Morrell, M.D., medical director at Lynn Cancer InstituteJane Mendez, M.D., chief of breast surgery at Miami Cancer InstituteAna Botero, M.D., radiation oncologist at Miami Cancer Institute

El VIH hace parte de las enfermedades con mayor incidencia en América Latina, especialmente en República Dominicana donde se diagnosticaron y 2,819 pacientes con VIH en el 2020. Las personas infectadas con VIH tienen mayor riesgo de desarrollar ciertos tipos de cáncer, de modo que es fundamental educar acerca de la importancia de contar con expertos y clínicas que ofrezcan la mejor respuesta con tratamientos multidisciplinarios.Este año el Miami Cancer Institute, parte de Baptist Health South Florida, inauguró una clínica especializada para tratar a pacientes con VIH y cáncer, con el fin de brindar una atención multidisciplinaria complejidad que involucra tratar a pacientes con ambas condiciones.Conocemos más detalles al respecto con el Dr. Marcos Ruiz, jefe de Oncología de VIH y Trasplantación de Células Madre de Miami Cancer Institute.

El VIH hace parte de las enfermedades con mayor incidencia en América Latina, especialmente en República Dominicana donde se diagnosticaron y 2,819 pacientes con VIH en el 2020. Las personas infectadas con VIH tienen mayor riesgo de desarrollar ciertos tipos de cáncer, de modo que es fundamental educar acerca de la importancia de contar con expertos y clínicas que ofrezcan la mejor respuesta con tratamientos multidisciplinarios.Este año el Miami Cancer Institute, parte de Baptist Health South Florida, inauguró una clínica especializada para tratar a pacientes con VIH y cáncer, con el fin de brindar una atención multidisciplinaria complejidad que involucra tratar a pacientes con ambas condiciones.Conocemos más detalles al respecto con el Dr. Marcos Ruiz, jefe de Oncología de VIH y Trasplantación de Células Madre de Miami Cancer Institute.

Healing involves more than undergoing a medical procedure or taking a pill.  Increasingly, health care systems like Baptist Health South Florida are offering integrative therapies such as acupuncture, meditation, healthy foods, art therapy and pet therapy to meet the physical, emotional and spiritual needs of their patients. In this episode, host Jonathan Fialkow, M.D., explores the impacts integrative medicine can bring to patients' well being with expert guests from across Baptist Health.Guests:·      Beatriz Currier, M.D, medical director of the Cancer Patient Support Center at Miami Cancer Institute.·      Thi Squire, community garden manager with the Grow to Heal Program at Homestead Hospital·      Wally Majors, dog therapy volunteer at Bethesda Hospital East.Learn more about Miami Cancer Institute's Arts in Medicine program and the Grow2Heal initiative.

Racial and ethnic minorities are among the fastest growing of all communities in the United States, making up nearly 40% of the population. Yet studies show poorer health outcomes among minorities across a wide spectrum of diseases. This past year, we’ve seen that many people from minority groups are also at increased risk of getting sick and dying from COVID-19. National Minority Health Month in April highlights efforts to improve the health of people in racial and ethnic minority groups. One piece of this puzzle is aimed at increasing minority participation in clinical trials -- a priority for guest, Manmeet Ahluwalia, M.D., deputy director, chief scientific officer and chief of solid tumor medical oncology at Baptist Health’s Miami Cancer Institute.

A discussion about COVID Vaccines co-hosted by Michael Zinner, MD, CEO and Executive Medical Director, Miami Cancer Institute, and Health Channel host Olga Villaverde, with Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Atul Gawande, Author, Harvard Medical School; Harvard School of Public Health Researcher and member of the Biden Presidential COVID-19 Task Force, Dr. Henri Ford, Dean and Chief Academic Officer, University of Miami Leonard M. Miller School of Medicine, and Dr. Geeta Nayyar, Assistant Clinical Prof of Medicine of Florida International University

ONS member Lauren Suarez, RN, MSN, OCN®, CBCN®, nurse manager of radiation oncology at Miami Cancer Institute in Florida and member of the Miami-Dade ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss the ONS Guidelines™ for Cancer Treatment–Related Radiodermatitis and how oncology nurses can manage this treatment side effect. Suarez was also a member of the advisory panel that developed this clinical practice guideline, which published in November 2020. Music Credit: "Fireflies and Stardust" by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Episode Notes  Check out these resources from today's episode:  Complete this evaluation for free nursing continuing professional development.  ONS Guidelines™ for Cancer Treatment–Related Radiodermatitis  Clinical Journal of Oncology Nursing article: Patient Preference for Instructional Reinforcement Regarding Prevention of Radiation Dermatitis  Oncology Nursing Forum article: Radiodermatitis in Patients With Cancer: Systematic Review and Meta-Analysis  Other Oncology Nursing Podcast episodes on ONS Guidelines  Putting Evidence Into Practice: Radiodermatitis  Common Terminology Criteria for Adverse Events: Dermatitis Radiation Grading  National Cancer Institute: Skin and Nail Changes During Cancer Treatment  OncoLink: Skin Reactions From Radiation 

While the word mesothelioma may be familiar from various advertisements, most people will likely have never met someone diagnosed with this rare cancer. In this episode, we will discuss symptoms, diagnosis and treatments, including new approaches. Our guest to help us better understand this cancer is Dr. Rupesh Kotecha from Miami Cancer Institute.